
Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion on Wednesday, beating the consensus estimate of $4.97 billion.
The medical technology giant reported adjusted earnings of 75 cents, beating the consensus of 71 cents and the management guidance of 70-72 cents.